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Primary Hyperparathyroidism: Changing Patterns in 
Presentation and Treatment Decisions in the Eighties 
D. Sudhaker Rao, MBBS* 
A simple blood test, done because it is so cheap rather 
than because it is medically necessary, is leading to 
the diagnosis and treatment of people who didn't 
know they were sick and (often after evaluation and 
treatment), neither the doctor nor the patient know 
whether the patients are better off (1). 
In the beginning primary hyperparathyroidism (PHPT) was 
a disease of stones and bones, abdominal moans and groans 
with psychic overtones, and now "As mild primary hyper-
parathyroidism 'emerged' in the 60s and 70s, the pendulum 
swung away from reflexive surgical treatment....What is 
clear is that there is much more to be learned about this 'new 
disease'; meanwhile, the cauldron of controversy will 
remain well stirred" (2). 
More than a half century has elapsed since a parathyroid 
adenoma was successfully removed from a patient suffering 
from osteitis fibrosa cystica (3). From 1926 to approximately 
1960, PHPT was dominated by the usual manifestations that 
have become characteristic of this disease. With today's 
routine measurement of serum calcium, PHPT is now one 
of the most common endocrine disorders; current estimates 
indicate a prevalence of PHPT between 0 . 1 % and 0.5% 
(4,5), with a female preponderance. Because of early 
recognition and diagnosis, the clinical manifestations of 
PHPT have changed significantly through the years, with the 
majority of today's patients being asymptomatic (6-8). As 
mild asymptomatic PHPT emerged in the 70s, the initial 
conviction that every patient ought to be treated with 
surgery has come into question (9,10), and it is therefore 
necessary to reexamine whether all patients with PHPT 
should be treated with surgical or medical management. 
Already the enthusiasm for early surgery has waned, but the 
controversy regarding treatment remains unsettled (2,11), 
Spectrum of Clinical Manifestations 
Although PHPT is a disease of protean manifestations, in 
patients with this disease in the past, skeletal and renal 
complications accounted for more than 80% to 9 0 % of the 
presenting features (7,8,11-19), with gastrointestinal symp-
toms at a distant third. Even these modes of presentation 
have declined over the past two decades and continue to 
decline (Figure, Table I), The proportion of patients with 
bone disease or kidney stones had decreased precipitously 
Table I 
Clinical Manifestations of Hypercalcemia* 
Skeletal 
Renal 
Gastrointestinal 
Neuropsychiatric 
Cardiovascular 
Ocular and skin 
Nonspecific 
Arthritis 
Chondrocalcinosis 
Polyuria 
Nephrolithiasis 
Nephrocalcinosis 
Renal insufficiency 
Polydipsia 
Anorexia 
Nausea and vomiting 
Constipation 
Pancreatitis 
Memory impairment 
Headaches and lethargy 
Seizures and coma 
Arrhythmias 
Short QTc interval on EKG 
Hypertension 
Corneal calcification 
Soft tissue calcification 
Pruritus and "irr i table" eyes 
Weakness and tiredness 
Fatigue 
Arthralgia 
*Not necessarily those of underlying disease; 
information modified from D. S. Rao (21) 
by 1976 (Figure), but asymptomatic PHPT has steadily 
increased since that time. Consequently, skeletal symptoms 
as the presenting feature of PHPT have not been seen since 
1980 at Henry Ford Hospital, although nephrolithiasis 
continues to be present in a small number of patients (Rao, 
unpublished data, 1985, and Figure). Interestingly, the 
frequency of hypertension among patients with PHPT has 
remained stable despite a decline in every other manifesta-
tion of this disease. Contrary to previous reports (8,20), 
hypertension in these individuals is probably unrelated to 
hypercalcemia or excess parathyroid hormone secretion. 
Furthermore, the presentation of the disease is milder now, 
and in most patients the serum calcium level rarely exceeds 
11.5 mg/dL; however, it is not currently known whether any 
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Figure 
Changing pattern of presentation of pr i -
mary hyperparathyroidism: total of 1,966 
patients f rom 11 reporfed series between 
1948 and 1980 (7,8,11-19) and 58 patients 
f rom Henry Ford Hospital between 1980 
and 1983 (presented as 1983). Only two 
major manifestations of PHPT are used to 
construct the curves. A.Sx.: asymptomatic. 
Time scales are not at equal intervals. 
significant morbidity is associated with this degree of 
hypercalcemia. 
The least understood manifestations of PHPT are the 
neuromuscular and psychiatric symptoms. In general, the 
frequency and severity of these symptoms correlate with the 
degree of hypercalcemia and tend to decrease with the 
normalization of serum calcium. Other less frequent mani-
festations of PHPT are summarized in Table I (21), and 
clinical features are related to serum calcium level and not 
to the causes of hypercalcemia. 
Laboratory Investigations and Diagnostic 
Considerations 
Despite recent advances in understanding the pathophysiol-
ogy of altered mineral metabolism, hypercalcemia of long 
Table 11 
Clinical Criteria for Diagnosis of PHPT 
Major criteria 
Minor criteria 
Stable hypercalcemia (less than 12 mg/dL) 
Long duration (more than one year) 
Minimal fluctuations (less than 1 mg/dL) 
Presence of target organ effects* 
Hypophosphatemia (less than 2.5 mg/dL) 
Hyperchloremic acidosis (serum chloride more than 
106 mEq/L) 
Increased chloride/phosphate ratio (more than 35) 
Relative hypocalciuriat 
•Subperiosteal bone resorption, "salt and pepper" skull, osteopenia or 
osteoporosis, " b r o w n " tumors or bone fractures, and nephrolithiasis or 
nephrocalcinosis 
tLower urinary calcium excretion than would be expected for level of 
serum calcium since PTH enhances renal tubular reabsorption of 
calcium 
duration still remains the single best laboratory test for 
confirming the diagnosis of PHPT. Based on data from over 
300 patients with this disease, clinically useful criteria for 
the diagnosis of PHPT are summarized in Table II. With the 
availability of immunoassays for parathyroid hormone (PTH) 
and nephrogenous cyclic adenosine monophosphate 
(NcAMP), a more direct confirmation of the diagnosis of 
PHPT is possible. The immunologic heterogeneity of PTH 
in the blood and the finding of elevated NcAMP in patients 
with known malignancy have complicated the interpretation 
of these results. Each physician should therefore be familiar 
with the sensitivity and specificity of these tests (Table III). 
Various diagnostic possibilities based on PTH and NcAMP 
values in hypercalcemic patients are presented in Table IV 
(22), and along with the previously mentioned criteria (Table 
III), it should be relatively simple to confirm a diagnosis of 
PHPT in most hypercalcemic patients. 
Table lli 
Specificity of Tests in Diagnosis of PHPT 
Number Positive 
58 (71)* 
64 (71)* 
69 (71)* 
37 (61) 
Percent Positive 
8 2 % 
9 0 % 
9 7 % 
6 1 % 
Measurement 
Immunoreactive PTH 
NcAMPt 
TmP/GFRt 
24-hour urine calcium 
*Parentheses indicate total number of patients tested simultaneously 
'Nephrogenous cyclic AMP represents biologic expression of endoge-
nously secreted PTH and appears to be more sensitive than measure-
ment of serum PTH in diagnosis of PHPT. Similarly, tubular maximum 
for phosphate reabsorption (TmP/GER) also reflects endogenous PTH 
secretion, although TmP/GER may be influenced by serum calcium 
level independent of PTH secretion (22). 
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Table IV 
Diagnostic Possibilities Based on PTH and NcAMP Values in Patients w i th 
Hypercalcemia* 
Immunoreactive 
Parathyroid Hormone 
Increased 
Normal 
Decreased 
Nephrogenous 
Cyclic AMP 
Increased or normal 
Increased 
Decreased 
*Modified from M. Kleerekoper (22) 
Differential Diagnosis 
In general, every patient with hypercalcemia should be 
examined thoroughly for an occult malignancy or for a 
nonparathyroid cause for hypercalcemia. However, experi-
ence suggests that in most patients the diseases that cause 
hypercalcemia are obvious by history or physical examina-
tion, and further testing for an occult malignancy is usually 
nonrevealing; this is true for the associated cancers or the 
benign endocrine or nonendocrine tumors known to pro-
duce hypercalcemia. Certain general principles are helpful 
in predicting the presence of PHPT in a hypercalcemic 
patient. These guidelines include the following: 1) accidental 
discovery of hypercalcemia is almost always due to under-
lying PHPT and rarely to multiple myeloma or sarcoidosis; 
2) presence of nephrolithiasis in a patient with hypercalce-
mia is highly suggestive of PHPT; 3) when two diseases 
known to produce hypercalcemia coexist (eg, PHPT and 
malignancy, PHPT and hyperthyroidism, PHPT and sarcoi-
dosis), only one or the other condition is responsible for the 
hypercalcemia and not both; and 4) if one of the two 
diseases is PHPT, it is the PHPT that causes hypercalcemia 
and not the other condition (Rao, unpublished data, 1985). 
Medical and Surgical Treatment Decisions 
In view of the changing patterns in the presentation of PHPT, 
it is necessary to devise new criteria that will help select 
those patients at risk of developing complications so that 
early surgical intervention can be achieved. Unfortunately, 
no definitive studies are available to predict the natural 
history of this disease in any given patient (2). Based on a 
group of patients who did or did not receive operations, the 
criteria for surgical intervention in an asymptomatic patient 
is given in Table V. Many studies that are involved in 
evaluating these patients are not included in the decision-
making process because these tests lack evidence that they 
are predictors of significant morbidity. Parathyroidectomy 
is the treatment of choice in patients with symptomatic 
hypercalcemia or in those with evidence of target organ 
Diagnostic 
Consideration 
Primary or ectopic 
hyperparathyroidism 
Humoral hypercalcemia of 
malignancy 
Primary hyperparathyroidism 
Non-PTH mediated hypercalcemia 
Sarcoidosis 
Milk-alkali syndrome 
Calciferol poisoning 
involvement. The extent of surgery must be individualized, 
and selective parathyroidectomy is recommended for most 
patients (23). Routine subtotal parathyroidectomy (ie, re-
moval of three and one half of the remaining fourth gland) 
is to be discouraged except in a select group of patients with 
PHPT (23). The removal ofa single enlarged gland is curative 
in over 8 0 % of patients with PHPT, with the remaining 20% 
requiring subtotal parathyroidectomy. The risk of recurrent 
hyperparathyroidism or permanent postoperative hy-
poparathyroidism is approximately 5%. 
Management of patients with asymptomatic PHPT is most 
controversial (9-11). As parathyroidectomy is curative in 
most patients, some claim that it is best to operate on every 
patient as soon as the diagnosis is firmly established (14). 
The most common reasons for this approach include the 
high cost of following these patients indefinitely and the 
difficulty in supervising patients for any length of time. 
Although these presumptions may be true, the age group of 
patients with PHPT is such that most would be followed 
anyway for an unrelated medical condition. Furthermore, 
serum calcium should be measured only twice a year since 
hypercalcemia remains stable for a long period of time and 
has minimal fluctuations. Considering the problem of asymp-
tomatic PHPT from this perspective, the cost of caring for 
these patients is no more than that of an average person 
without this disease. If a physician is concerned about lapses 
Table V 
Uti l i ty of Various Tests in Management of PHPT 
Test Results Favoring Surgical Intervention* 
Serum calcium consistently above 12 mg/dL 
Decreased glomerular filtration rate adjusted for age 
Decreased bone mineral content adjusted for age, sex, and race 
Presence of target organ effects (bone or stone disease) 
Tests Not Helpful in Deciding Surgical Intervention 
Serum immunoreactive PTH 
Nephrogenous cAMP 
Tubular reabsorption of phosphate (TmP/GFR) 
Urinary calcium excretion 
'Even in absence of symptoms 
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in follow-up, surgery may be considered even in the absence 
of symptoms or signs of PHPT. 
No effective pharmaceutical preparation is currently avail-
able for the long-term treatment of PHPT (24). Several 
medications used in the management of symptomatic 
hypercalcemic patients have varying results and are gener-
ally ineffective for most patients (25). Although estrogens 
have been shown to be beneficial in lowering serum calcium 
in patients with PHPT (26), the response is unpredictable in 
any given patient. In addition, estrogen dose required to 
lower serum calcium may be unacceptably high. In selected 
postmenopausal white females in whom surgery is either 
contraindicated or not opted by the patient, estrogen 
therapy may be considered if serum calcium is consistently 
above 12 mg/dL. 
References 
1. Bishop JE. Soaring medical costs and the Mayo "epidemic." The Wall 
Street Journal, February 26, 1980. 
2. Hodgson SF, Heath HI I I . Asymptomatic primary hyperparathyroidism: 
Treat or follow? Mayo Clin Proc 1981;56:521-3. 
3. Mandl F. Klinisches und experimentelles zur Erage der lokalisierten und 
generalisierten Osteitis Fibrosa. Arch Klin Chir 1926;143:1-46. 
4. Boonstra CE, Jackson CE. Hyperparathyroidism detected by routine 
serum calcium analysis. Ann Intern Med 1965;63:468-74. 
5. Heath H 111, Hodgson SF, Kennedy MA. Primary hyperparathyroidism 
incidence, morbidity, and potential economic impact in a community. 
N Engl J Med 1 980;302;189-93. 
6. Britton DC, Johnston IDA, Thompson MH, Fleming LB. The outcome 
of treatment and changes in presentation of primary hyperparathyroid-
ism. Brit J Surg 1973;60:782-5. 
7. Mundy CR, Cove DH, Fisken R. Primary hyperparathyroidism: 
Changes in the pattern of clinical presentation. Lancet 1980;1:1317-
20. 
8. Lafferty FW. Primary hyperparathyroidism: Changing clinical spec-
trum, prevalence of hypertension, and discriminant analysis of labora-
tory tests. Arch Intern Med 1981;141:1761-6. 
9. Rohl PG, Wilkinson M, Clifton-Bligh P, Posen S. Hyperparathyroidism: 
Experience with treated and untreated patients. Med J Austr 
1981;1:519-21. 
10. Posen S, Clifton-Bligh P, Reeve TS, Wagstaffe C, Wilkinson M. Is 
parathyroidectomy of benefit in primary hyperparathyroidism? Quart 
J Med 1985;54:241-51. 
11. Scholz DA, Purnell DC. Asymptomatic primary hyperparathyroidism: 
10-year prospective study. Mayo Clin Proc 1981;56:473-8. 
12. Albright F, Reifenstein CE. The parathyroids and metabolic bone 
disease. Baltimore: Williams & Wilkins Co, 1948:46-114. 
13. Hellstrom J, Ivemark Bl. Primary hyperparathyroidism: Clinical and 
structural findings in 138 cases. Acta Chir Scand [Suppl] 1962;294:1-
113. 
14. Keating RF Jr. Diagnosis of primary hyperparathyroidism. JAMA 
1961;178:547-55. 
15. McGeown M C . Sex, age and hyperparathyroidism. Lancet 
1969:1:887-8. 
16. Purnell DC, Smith LH, Scholz DA, Elveback LR, Arnaud DC. Primary 
hyperparathyroidism: A prospective clinical study. Am J Med 
1971;50:670-8. 
1 7. WangCA. Surgery of the parathyroid glands. Adv Surg 1971 ;5:109-27. 
18. Mallette LE, Bilezikian JP, Heath DA, Aurbach GD. Primary hyper-
parathyroidism: Clinical and biochemical features. Medicine 
1974;53:127-46. 
19. Watson L. Primary hyperparathyroidism. Clin Endocrinol Metab 
1974;3:215-35. 
20. Madhaven T, Frame B, Block MA. Influence of surgical correction of 
primary hyperparathyroidism on associated hypertension. Arch Surg 
1970;100:212-4. 
21 . Rao DS. Disorders of divalent ion metabolism. In: Stein ]H, ed. Internal 
medicine. Boston: Little Brown, 1983:1836-45. 
22. Kleerekoper M. Laboratory evaluation of abnormal bone and mineral 
homeostasis. In: Stein JH, ed. Internal medicine. Boston: Little Brown, 
1983:1829-36. 
23. Block MA, Frame B, Jackson CE, Horn RC. The extent of operation 
for primary hyperparathyroidism. Arch Surg 1974;109:798-801. 
24. Bilezikian JP. The medical management of primary hyperparathyroid-
ism. Ann Intern Med. 1982;96:198-202. 
25. Rao DS, Kleerekoper M, Parfitt AM, Oliver I, Frame B, Thompson D. 
Effect of propranolol on serum calcium in patients with primary 
hyperparathyroidism. In: Copp DH, Talmage RV, eds. Endocrinology 
of calcium metabolism. Amsterdam: Excerpta Medica, 1978:426. 
26. Marcus R, Madvig P, Crum M, Pont A, Kosek J. Conjugated estrogens 
in the treatment of postmenopausal women with hyperparathyroidism. 
Ann Intern Med 1984;1 00:633-40. 
197 
